Galdakao | Pamplona | Requena I | Requena II | Seville | Tenerife | Terrassa I | Terrassa II | Terrassa III | Zaragoza I | Zaragoza II | Total | |
Study years | 2003–2009 | 2004–2009 | 1998–2004 | 1999–2004 | 1999–2010 | 1997–2010 | 1996–2010 | 1998–2010 | 2003–2010 | 1998–? | 1997–2007 | |
Cohort entry | Stability | Stability | Stability | Stability | Stability | Stability | Discharge | Re-admitted | Discharge | Stability | Stability | |
Subjects n | 543 | 190 | 174 | 186 | 596 | 275 | 135 | 66 | 181 | 137 | 1150 | 3633 |
Person-years | 2303.67 | 795.58 | 561.25 | 557.83 | 1567.50 | 1271.00 | 584.00 | 301.75 | 704.17 | 717.17 | 6520.25 | 15878.17 |
Age years | 68.3±8.3 | 65.2±8.4 | 72.1±8.9 | 70.9±8.0 | 65.8±9.6 | 62.9±9.9 | 72.2±9.2 | 71.7±8.9 | 71.9±9.8 | 65.8±7.6 | 63.4±9.4 | 66.4±9.7 |
Sex male | 522 (96) | 159 (84) | 173 (99) | 185 (99) | 564 (95) | 217 (79) | 124 (92) | 65 (98) | 172 (95) | 136 (99) | 1072 (93) | 3389 (93) |
Pack-years of smoking | 48±26 | 53±27 | 61±33 | 63±36 | 50±22 | 65±27 | NA | NA | 58±36 | 57±25 | 52±25 | 54±36 |
Smoking status | ||||||||||||
Former | 414 (76) | 119 (63) | 131 (76) | 151 (81) | 453 (76) | 140 (57) | 96 (72) | 57 (86) | 132 (75) | 99 (73) | 740 (66) | 2532 (71) |
Current | 114 (21) | 71 (37) | 39 (22) | 32 (17) | 143 (24) | 103 (43) | 23 (17) | 9 (14) | 41 (23) | 37 (27) | 384 (34) | 996 (28) |
Never | 15 (3) | 0 (0) | 3 (2) | 3 (2) | 0 (0) | 0 (0) | 14 (11) | 0 (0) | 3 (2) | 0 (0) | 0 (0) | 38 (1) |
BMI | 28±4 | 27±5 | 28±4 | 28±5 | 29±6 | 27±5 | 26±5 | 26±4 | 28±5 | 28±5 | 28±5 | 28±5 |
FEV1 % pred | 55±13 | 69±19 | 48±17 | 46±17 | 43±13 | 56±21 | 41±13 | 30±13 | 45±14 | 48±18 | 62±20 | 54±19 |
GOLD stage | ||||||||||||
Mild | 1 (0.2) | 64 (34) | 5 (3) | 10 (5) | 1 (0.2) | 41 (15) | 0 (0) | 1 (2) | 0 (0) | 6 (5) | 239 (20) | 368 (10) |
Moderate | 357 (66) | 92 (48) | 63 (42) | 47 (25.4) | 202 (34) | 112 (41) | 31 (23) | 2 (3) | 63 (35) | 59 (43) | 584 (51) | 1612 (45) |
Severe | 167 (31) | 28 (15) | 57 (38) | 100 (54.1) | 292 (49) | 95 (34) | 79 (58) | 21 (34) | 94 (53) | 50 (37) | 272 (24) | 1255 (35) |
Very severe | 18 (3) | 6 (3) | 25 (17) | 28 (15.1) | 101 (17) | 27 (10) | 25 (19) | 38 (61) | 22 (12) | 21 (15) | 55 (5) | 366 (10) |
mMRC dyspnoea score | 2.4±0.9 | 2.0±1.1 | 2.8±1.2 | 3.1±1.1 | 2.4±1.0 | 2.1±1.2 | 3.4±1.3 | 3.0±1.0 | 3.7±1.2 | 2.7±1.1 | 2.6±1.1 | 2.6±1.1 |
6MWD m | 409±92 | 463±114 | 434±125 | 380±112 | NA | 487±87 | NA | 218±77 | 330±106 | 449±92 | 456±154 | 397±130 |
Past year exacerbations | 0.6±0.7 | NA | 0.3±0.6 | 0.6±0.9 | 1.2±1.9 | 0.4±0.7 | 1.0±1.4 | 1.8±1.2 | 1.3±2.0 | NA | 0.9±2.2 | 0.9±1.8 |
Charlson index | 1.4±1.4 | 1.6±1.3 | 1.1±1.6 | 0.8±0.9 | 1.1±1.8 | 2.0±1.7 | 1.2±1.0 | 0.6±0.9 | 1.2±1.3 | 2.5±1.1 | 0 | 1.3±1.5 |
SGRQ total | 39±20 | NA | 55±25 | 47±19 | NA | 34±22 | 51±19 | 56±16 | 49±13 | 45±19 | NA | 43±20 |
Data are presented as n (%) or mean±sd, unless otherwise stated. BMI: body mass index; FEV1: forced expiratory volume in 1 s; % pred: % predicted; GOLD: Global Initiative for Chronic Obstructive Lung Disease; mMRC: modified Medical Research Council; 6MWD: 6-min walk distance; SGRQ: St George’s Respiratory Questionnaire; NA: not available. Note: The Zaragoza II cohort selected COPD patients without comorbidities at baseline, so Charlson is 0 by definition.